NUCLEIC ACID LIPID PARTICLE VACCINE ENCAPSULATING HPV MRNA
The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof:wherein R<sup>1</sup> and R<sup>2</sup> each independently represent a C<sub>1</sub>-C<sub>3</sub> alkyl group;L<sup>1</sup> represents a C<sub>17</sub>-C<sub>19</sub> alkenyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups;L<sup>2</sup> represents a C<sub>10</sub>-C<sub>19</sub> alkyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups or a C<sub>10</sub>-C<sub>19</sub> alkenyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups; andp is 3 or 4..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 14. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
NIWA TAKAKO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-14, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 |
|---|
| Patentnummer: |
EP4059515 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA015966453 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA015966453 | ||
| 003 | DE-627 | ||
| 005 | 20240301102126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA015966453 | ||
| 035 | |a (EPA)EP4059515 | ||
| 035 | |a (EPA)75912775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a NIWA TAKAKO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NUCLEIC ACID LIPID PARTICLE VACCINE ENCAPSULATING HPV MRNA |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-14, Last update posted on www.tib.eu: 2024-02-27, Last updated: 2024-03-01 | ||
| 520 | |a The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof:wherein R<sup>1</sup> and R<sup>2</sup> each independently represent a C<sub>1</sub>-C<sub>3</sub> alkyl group;L<sup>1</sup> represents a C<sub>17</sub>-C<sub>19</sub> alkenyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups;L<sup>2</sup> represents a C<sub>10</sub>-C<sub>19</sub> alkyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups or a C<sub>10</sub>-C<sub>19</sub> alkenyl group which may have one or a plurality of C<sub>2</sub>-C<sub>4</sub> alkanoyloxy groups; andp is 3 or 4. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SUZUKI TAKASHI |4 aut | |
| 700 | 0 | |a KOIZUMI MAKOTO |4 aut | |
| 700 | 0 | |a JONAI NAO |4 aut | |
| 700 | 0 | |a ONODERA YOSHIKUNI |4 aut | |
| 700 | 0 | |a TAKESHITA FUMIHIKO |4 aut | |
| 700 | 0 | |a ISHII KEN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 14. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75912775/publication/EP4059515A1?q=EP4059515 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 14 |c 02 | ||